Patents Assigned to University of the Witwatersrand, Johannesburg
  • Patent number: 10973766
    Abstract: The invention relates to an oral polymeric pharmaceutical dosage form which comprises a thermoresponsive eutectic composition which is solid at or about room temperature and fluid at or about body temperature, the eutectic composition mixed together with a crosslinking agent and an active pharmaceutical ingredient (API) to form an API loaded region; and a porous polymeric composition at least partially surrounding the API loaded region to protect the API when the dosage form is in a stomach of the human or animal body, the porous polymeric composition allowing the ingress of water to contact the crosslinking agent thereby facilitating the crosslinking agent to cause crosslinking of the porous polymeric composition, which crosslinked porous polymeric composition allows controlled egress of API via egress of fluid thermoresponsive eutectic composition at the intestine. In a preferred embodiment, the dosage form further comprises a coating there around.
    Type: Grant
    Filed: June 27, 2016
    Date of Patent: April 13, 2021
    Assignee: UNIVERSITY OF THE WITWATERSRAND, JOHANNESBURG
    Inventors: Viness Pillay, Lisa Claire Du Toit, Yahya Essop Choonara, Bibi F. Choonara, Pradeep Kumar, Pierre Pavan Demarco Kondiah
  • Publication number: 20200405821
    Abstract: A polyacrylonitrile (PANi) based pharmaceutical composition providing a porous implant for use in treating spinal cord trauma and/or spinal cord injury. Particularly a pharmaceutical composition including polyacrylonitrile (PANi) and/or elastin (E) and/or collagen (C) to form a PANi-E and/or PANi-C and/or a PANi-EC polymer network. Particularly, a pharmaceutical composition including polyacrylonitrile (PANi), elastin (E), and collagen (C) together forming a polyacrylonitrile (PANi), elastin (E), collagen (C) polymer network (PANi-E-C), wherein the polyacrylonitrile (PANi) may be crosslinked to form a crosslinked interpenetrating polyacrylonitrile (PANi), elastin (E) and collagen (C) polymer network (xpi-PANi-E-C), and wherein secondary protein structures of elastin (E) and collagen (C) reorientate. The disclosure extends to use of the pharmaceutical composition in the treatment of spinal cord trauma and/or spinal cord injury.
    Type: Application
    Filed: December 19, 2018
    Publication date: December 31, 2020
    Applicant: UNIVERSITY OF THE WITWATERSRAND, JOHANNESBURG
    Inventors: Pradeep KUMAR, Viness PILLAY, Yahya Essop CHOONARA, Girish MODI
  • Publication number: 20200299843
    Abstract: THIS invention relates to a method of applying an antimicrobial surface coating to a substrate, and more particularly to a method of applying an antimicrobial surface coating to a polymeric substrate manufactured by way of additive manufacturing. The method includes the steps of providing a body to be coated, the body having a surface area and cold spraying an antimicrobial metal powder on at least part of the surface area of the body so as to form an antimicrobial coating on the body. The method is characterized in that the body is made from a polymeric material by way of an additive manufacturing process.
    Type: Application
    Filed: September 25, 2018
    Publication date: September 24, 2020
    Applicant: University of the Witwatersrand, Johannesburg
    Inventors: Ionel BOTEF, Michael David Ivan LUCAS, Sandy van VUUREN
  • Patent number: 10774391
    Abstract: The present invention relates to a recombinant bacterium based on a non-pathogenic bacterium that has a modified genome containing a nucleic acid of interest from a pathogen that is detected by a molecular diagnostic assay and that mimics the diagnostic profile of the pathogen. The invention further relates to a diagnostic control composition comprising the recombinant bacterium and to methods for producing the recombinant bacterium. The recombinant bacterium is a safe, reliable quality control for the detection of pathogens such as Mycobacterium tuberculosis and Staphylococcus aureus. The invention also relates to a kit comprising either the recombinant bacterium, compositions containing the recombinant bacterium or bacteria produced according to the method of the invention.
    Type: Grant
    Filed: March 31, 2017
    Date of Patent: September 15, 2020
    Assignee: UNIVERSITY OF THE WITWATERSRAND, JOHANNESBURG
    Inventors: Bavesh Davandara Kana, Edith Erika Machowski
  • Patent number: 10675592
    Abstract: An acid mine drainage (AMD) treatment means comprising polyethersulfone (PES) having dispersed therein hydroxy-sodalite (H-SOD) so as to form a membrane is described. The PES-H-SOD membrane is suitable for treatment of acid mine drainage (AMD) by providing a filtration means to remove toxic chemicals, including but not limited to heavy metals. The invention extends to a method of manufacturing the acid mine drainage (AMD) treatment means.
    Type: Grant
    Filed: May 30, 2016
    Date of Patent: June 9, 2020
    Assignee: University of the Witwatersrand, Johannesburg
    Inventors: Michael Olawale Daramola, Bongile Silinda, Sandile Aubrey Masondo
  • Patent number: 10648856
    Abstract: This invention relates to a method of and a system for determining a beam quality factor (VQF) of a beam of light having a transverse electric field that may be scalar, vector, or a combination thereof, wherein the VQF is a measure of the degree of vectorness of the beam of light varying between pure scalar and pure vector. The beam is typically a laser beam, wherein the method comprises receiving an input laser beam to be analysed and splitting the received beam of light into two orthogonal components. A predetermined number of modes or states per orthogonal component is then detected and an on axis intensity of each detected mode or state detected is measured. The measured intensities is then used to calculate the VQF in terms using at least one quantum mechanical entanglement measure.
    Type: Grant
    Filed: June 19, 2017
    Date of Patent: May 12, 2020
    Assignee: UNIVERSITY OF THE WITWATERSRAND, JOHANNESBURG
    Inventor: Andrew Forbes
  • Patent number: 10519222
    Abstract: The present invention relates anti-HIV therapies and prophylaxis. Specifically, the invention relates to broadly neutralizing antibodies against HIV-1, nucleic acids encoding these antibodies, vectors comprising the nucleic acids and cells and pharmaceutical compositions Comprising said vectors and/or antibodies. The present invention also relates to use of the antibodies and/or vectors for the treatment and/or prevention of HIV-1 infection in a subject. Furthermore, the invention also relates to a kit containing the antibodies of the invention.
    Type: Grant
    Filed: February 27, 2015
    Date of Patent: December 31, 2019
    Assignees: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK, CENTRE FOR THE AIDS PROGRAMME OF RESEARCH IN SOUTH AFRICA, UNIVERSITY OF THE WITWATERSRAND, JOHANNESBURG, NATIONAL HEALTH LABORATORY SERVICE
    Inventors: Chaim Aryeh Schramm, Jason Gorman, John Mascola, Lawrence Stewart Shapiro, Lynn Morris, Nicole Amy Doria-Rose, Penelope Linda Moore, Peter Dak Pin Kwong, Salim Safurdeen Abdool Karim
  • Publication number: 20190394030
    Abstract: This invention relates generally to a method and system for hybrid classical-quantum communication. The method comprises transmitting a single photon having a particular quantum state over a communication medium using a quantum mode set; and transmitting a classical light beam over the same communication medium using a classical mode set, wherein the classical and quantum mode sets comprise non-separable modes in common. The non-separable modes in common may be two degrees of freedom of a single photon or classical light and may thus be spatial modes in one or more indexes, and polarisation. The invention relates also to a system to implement the method accordingly.
    Type: Application
    Filed: January 23, 2018
    Publication date: December 26, 2019
    Applicant: University of The Witwatersrand, Johannesburg
    Inventors: Andrew FORBES, Bienvenu NDAGANO,, Isaac NAPE, Mitchell COX, Carmelo ROSALES-GUZMAN
  • Patent number: 10478527
    Abstract: This invention relates to biodegradable implants comprising a hydrogel carrier matrix having dispersed therein a multitude of particles, wherein each of the multitude of particles and/or the hydrogel carrier matrix includes an active pharmaceutical ingredient (API) for the treatment of transected peripheral nerve injuries. Each of the multitude of particles and/or the hydrogel carrier matrix includes pristine polymer particles, preferably the pristine polymer particles may be polymethylmethacrylate polymers and derivatives thereof, preferably poly(methacrylic-co-methyl methacrylate) (PMMA). The spheroidal particles may each be formed from an outer shell including a chitosan (CHT) poly(methacrylic-co-methyl methacrylate) (PMMA) polyelectrolyte complex (CHT-PMMA-PEC) and an inner core including crosslinked chitosan having dispersed therein PMMA nanoparticles.
    Type: Grant
    Filed: September 5, 2016
    Date of Patent: November 19, 2019
    Assignee: University of the Witwatersrand, Johannesburg
    Inventors: Viness Pillay, Yahya Essop Choonara, Pradeep Kumar, Lisa Claire Du Toit, Poornima Ramburrun
  • Patent number: 10211126
    Abstract: This invention relates to a method of manufacturing an object with microchannels provides therethrough, and more particularly, but not exclusively, to a method of manufacturing a micro heat exchanger with microchannels provided therethrough. The method includes the steps of providing a metal base layer made from a first metal; forming a plurality of spaced apart ridges, made from a second metal, on the base layer; depositing more of the first metal onto the ridges in order to cover the ridges; and removing the ridges using a chemical etching process so as to produce microchannels in a body made of the first metal.
    Type: Grant
    Filed: October 13, 2015
    Date of Patent: February 19, 2019
    Assignee: UNIVERSITY OF THE WITWATERSRAND, JOHANNESBURG
    Inventors: Agripa Hamweendo, Ionel Botef
  • Patent number: 10080816
    Abstract: This invention relates to a wound dressing, particularly to a stimuli responsive wound dressing comprising a lyophilized hyaluronic acid (HA) hydrogel, and a plurality of devices embedded within said lyophilized hyaluronic acid hydrogel. Each of the plurality of devices including chitosan and hypromellose and may be formed as biofilms and/or electrospun fiber mats.
    Type: Grant
    Filed: June 5, 2015
    Date of Patent: September 25, 2018
    Assignee: University of the Witwatersrand, Johannesburg
    Inventors: Viness Pillay, Yahya Essop Choonara, Pradeep Kumar, Lisa Claire Du Toit, Naeema Mayet
  • Patent number: 10040724
    Abstract: The present invention provides for carbide ceramic matrix composite comprising Cf/C—SiC-xMC wherein Cf/C is a carbon fiber reinforced carbon matrix, x is at least 2, and wherein MC are carbides of transition metals with M being at least two different transition metals selected from the group consisting of titanium, zirconium, hafnium, vanadium, niobium, tantalum, chromium, molybdenum, and tungsten. The invention further provides for a method for manufacturing the composite.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: August 7, 2018
    Assignees: University of the Witwatersrand, Johannesburg, Fraunhofer-Gesellschaft zur Forderung der Angewandten Forschung E.V.
    Inventors: Phylis Sarah Makurunje, Iakovos Sigalas, Mathias Herrmann
  • Publication number: 20180193271
    Abstract: The invention relates to an oral polymeric pharmaceutical dosage form which comprises a thermoresponsive eutectic composition which is solid at or about room temperature and fluid at or about body temperature, the eutectic composition mixed together with a crosslinking agent and an active pharmaceutical ingredient (API) to form an API loaded region; and a porous polymeric composition at least partially surrounding the API loaded region to protect the API when the dosage form is in a stomach of the human or animal body, the porous polymeric composition allowing the ingress of water to contact the crosslinking agent thereby facilitating the crosslinking agent to cause crosslinking of the porous polymeric composition, which crosslinked porous polymeric composition allows controlled egress of API via egress of fluid thermoresponsive eutectic composition at the intestine. In a preferred embodiment, the dosage form further comprises a coating there around.
    Type: Application
    Filed: June 27, 2016
    Publication date: July 12, 2018
    Applicant: UNIVERSITY OF THE WITWATERSRAND, JOHANNESBURG
    Inventors: Viness PILLAY, Lisa Claire DU TOIT, Yahya Essop CHOONARA, Bibi F. CHOONARA, Pradeep KUMAR, Pierre Pavan Demarco KONDIAH
  • Patent number: 9808418
    Abstract: A pH responsive and mucoadhesive pharmaceutical dosage form for the release of a pharmaceutically active agent is described. The dosage form includes a mucoadhesive layer for site-specific mucoadhesion, a water-insoluble outer layer, and an intermediate layer including one or more pharmaceutically active agents for site-specific delivery. The different membranous layers perform different functions in order to create a drug delivery system which is able to deliver a drug to a specific site, for a particular period of time and with a specific drug release pattern. The dosage form can have two or more intermediate layers, each layer comprising an active agent. The mucoadhesive layer can also include an active agents. The dosage form is preferably an oral or buccal delivery form for release of the active agent into the gastro intestinal tract. The intermediate layer can be an electrospun fibrous membrane layer containing the active agent.
    Type: Grant
    Filed: November 28, 2011
    Date of Patent: November 7, 2017
    Assignee: UNIVERSITY OF THE WITWATERSRAND, JOHANNESBURG
    Inventors: Viness Pillay, Rubina Perveen Shaikh, Yahya Essop Choonara, Lisa Claire Du Toit
  • Publication number: 20160361413
    Abstract: The invention relates to a method of modulating concentration of Alzheimer's Disease (AD) relevant proteins amyloid precursor protein (APP), beta (?) and gamma (?) secretases and amyloid beta peptide (A?), and also relates to a method of reducing A? shedding. Furthermore, this invention extends to a compound for use in the treatment of AD, and also to a method of treating AD.
    Type: Application
    Filed: May 10, 2016
    Publication date: December 15, 2016
    Applicant: UNIVERSITY OF THE WITWATERSRAND, JOHANNESBURG
    Inventors: Stefan Franz Thomas Weiss, Katarina Jovanovic, Danielle Gonsavles, Bianca Da Costa Dias, Stefan Knackmuss, Uwe Reusch, Melvyn Little, Marc Saul Weinberg
  • Publication number: 20160362479
    Abstract: The present invention relates anti-HIV therapies and prophylaxis. Specifically, the invention relates to broadly neutralizing antibodies against HIV-1, nucleic acids encoding these antibodies, vectors comprising the nucleic acids and cells and pharmaceutical compositions Comprising said vectors and/or antibodies. The present invention also relates to use of the antibodies and/or vectors for the treatment and/or prevention of HIV-1 infection in a subject. Furthermore, the invention also relates to a kit containing the antibodies of the invention.
    Type: Application
    Filed: February 27, 2015
    Publication date: December 15, 2016
    Applicants: The United states of America, as represented by the Secretary, Department of Health and Human Serv, The Trustees of Columbia University in the City of New York, Centre for the AIDS Programme of Research in South Africa, University of the Witwatersrand, Johannesburg, National Health Laboratory Service
    Inventors: Chaim Aryeh Schramm, Jason Gorman, John Mascola, Lawrence Stewart Shapiro, Lynn Morris, Nicole Amy Doria-Rose, Penelope Linda Moore, Peter Dak Pin Kwong, Salim Safurdeen Abdool Karim
  • Patent number: 9439863
    Abstract: This invention relates to pharmaceutical dosage forms, particularly to pH dependent pharmaceutical dosage forms with enhanced and/or prolonged distribution of a pharmaceutical compound at a target site. More specifically, this invention relates to a controlled release intravaginal pharmaceutical dosage form and, more particularly, to a pharmaceutical dosage form which comprises microspheres encapsulated and/or embedded within a bioerodible polymeric matrix, together the microspheres and the matrix are formed into a caplet and/or tablet.
    Type: Grant
    Filed: February 8, 2013
    Date of Patent: September 13, 2016
    Assignee: University of the Witwatersrand, Johannesburg
    Inventors: Viness Pillay, Yahya Essop Choonara, Felix Mashingaidse, Pradeep Kumar
  • Patent number: 9422563
    Abstract: Nucleic acid aptamers which bind specifically to or are internalised into cells expressing a CD7 cell-surface receptor are disclosed. The aptamers comprise a nucleic acid molecule having a sequence which is at least 80% identical to 5?-GG-GAGACAAGAAUAAGCAUG-R1-UUCGACAGGAGGCUCACAACAGnynz-3? (SEQ ID NO: 3). The aptamers can be linked to therapeutic or diagnostic molecules, and can be used to deliver the therapeutic or diagnostic molecules to cells expressing the CD7 receptor. The aptamers can also be used as detection tools.
    Type: Grant
    Filed: March 18, 2014
    Date of Patent: August 23, 2016
    Assignee: University of the Witwatersrand, Johannesburg
    Inventors: Laura Ann Millroy, Makobetsa Abel Khati, Mark Saul Weinberg
  • Patent number: 9365647
    Abstract: The invention relates to a method of modulating concentration of Alzheimer's Disease (AD) relevant proteins amyloid precursor protein (APP), beta (?) and gamma (?) secretases and amyloid beta peptide (A?), and also relates to a method of reducing A? shedding. Furthermore, this invention extends to a compound for use in the treatment of AD, and also to a method of treating AD.
    Type: Grant
    Filed: September 19, 2012
    Date of Patent: June 14, 2016
    Assignee: UNIVERSITY OF THE WITWATERSRAND, JOHANNESBURG
    Inventors: Stefan Franz Thomas Weiss, Katarina Jovanovic, Danielle Gonsavles, Bianca Da Costa Dias, Stefan Knackmuss, Uwe Reusch, Melvyn Little, Marc Saul Weinberg
  • Patent number: 9352300
    Abstract: This invention relates to a titanium dioxide catalyst particle, the catalyst particle comprising rutile nanorods having metal nanoparticles deposited at or near the free ends of the nanorods, which is suitable to catalyze reactions after exposure to temperatures above 550 deg C. The invention also provides for the use of a catalyst particle in catalyzing reactions and a method of catalyzing reactions, the catalyst particle being suitable to catalyze reactions after exposure to temperatures about 550 deg C.
    Type: Grant
    Filed: August 19, 2012
    Date of Patent: May 31, 2016
    Assignee: University of the Witwatersrand, Johannesburg
    Inventors: Dean Howard Barrett, Paul John Franklyn